Compare ResMed Inc. (RMD) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs SpaceX — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while SpaceX trades at $125.26 (market cap $1.58T). The key difference: SpaceX is far larger — about 54.8× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.21% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| RMD | SPCX | |
|---|---|---|
Market Cap | $28.81B | $1.58T |
Sector | Health | Technology |
52-Week High | $293.73 | $202.09 |
52-Week Low | $182.82 | $119.85 |
Enterprise Value | $27.99B | $1.59T |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
SPCX trades at $123.46, down 0.43% amid bearish technical signals despite recent rebound attempts. The company shows strong revenue growth with $18.67B in 2025 but faces significant profitability challenges with a -45% net income margin. Analyst consensus remains strongly bullish with a $237.78 price target, though upcoming August earnings and share unlock events create near-term uncertainty.
While SpaceX maintains strong revenue momentum and AI infrastructure potential, investors face substantial risks from persistent losses, high valuations, and imminent share dilution. The stock's technical weakness contrasts with Wall Street's long-term optimism, creating a high-risk, high-reward scenario dependent on upcoming earnings execution and competitive positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
